Literature DB >> 12581899

A novel tumorigenic human prostate epithelial cell line (M2205): molecular cytogenetic characterization demonstrates C-MYC amplification and jumping translocations.

Colleen Jackson-Cook1, Ying Zou, Kristi Turner, Caroline Astbury, Joy Ware.   

Abstract

The paucity of cell lines from early-stage prostate cancer tumors has hindered the recognition of genetic and cellular changes that are associated with the acquisition of tumorigenesis. We describe the chromosomal complement of a novel tumorigenic prostate epithelial cell subline, called M2205, that acquired only three new, consistent chromosomal changes (from those present in the SV40T antigen immortalized parental cell line, P69SV40TAg) when it attained tumor-forming potential. The consistent changes, which were fully characterized using GTG-banding, CBG-banding, silver staining, fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and spectral karyotyping (SKY), involved segmental jumping translocations and resulted in gains in the copy number of genes located on the distal long arm of chromosome 8 (8q22 to 8q24.3), including c-myc. Furthermore, the jumping translocations also resulted in ribosomal genes being present in multiple, tandem copies next to the chromatin from 8q. Given the relatively small number of cytogenetic changes present, this subline provides a means for better understanding the cellular changes associated with the acquired chromosomal imbalances. Further studies of this subline could also provide insight as to the mechanism or mechanisms leading to the formation of jumping translocations, as well as potential position effects resulting from the relocation of ribosomal genes next to other cellular genes or oncogenes.

Entities:  

Mesh:

Year:  2003        PMID: 12581899     DOI: 10.1016/s0165-4608(02)00665-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

1.  Mutations in the G-quadruplex silencer element and their relationship to c-MYC overexpression, NM23 repression, and therapeutic rescue.

Authors:  Cory L Grand; Tiffanie J Powell; Raymond B Nagle; David J Bearss; Denise Tye; Mary Gleason-Guzman; Laurence H Hurley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

2.  Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer.

Authors:  Jin Zhao; Xin-Yang Wu; Xiao-Hui Ling; Zhuo-Yuan Lin; Xin Fu; Ye-Han Deng; Hui-Chan He; Weide Zhong
Journal:  Med Oncol       Date:  2013-02-03       Impact factor: 3.064

3.  Cytogenetic characterization of HB2 epithelial cells from the human breast.

Authors:  Fabio Caradonna; Claudio Luparello
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-08-27       Impact factor: 2.416

4.  Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.

Authors:  Steffen Wedel; Lukasz Hudak; Jens-Michael Seibel; Jasmina Makarević; Eva Juengel; Igor Tsaur; Ana Waaga-Gasser; Axel Haferkamp; Roman A Blaheta
Journal:  BMC Cancer       Date:  2011-08-25       Impact factor: 4.430

5.  Karyotypic Flexibility of the Complex Cancer Genome and the Role of Polyploidization in Maintenance of Structural Integrity of Cancer Chromosomes.

Authors:  Christina Raftopoulou; Fani-Marlen Roumelioti; Eleni Dragona; Stefanie Gimelli; Frédérique Sloan-Béna; Vasilis Gorgoulis; Stylianos E Antonarakis; Sarantis Gagos
Journal:  Cancers (Basel)       Date:  2020-03-05       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.